Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Get Free Report) CEO Mihael Hristos Polymeropoulos purchased 10,000 shares of Vanda Pharmaceuticals stock in a transaction on Tuesday, February 25th. The shares were acquired at an average cost of $4.46 per share, for a total transaction of $44,600.00. Following the completion of the transaction, the chief executive officer now owns 2,331,730 shares of the company's stock, valued at $10,399,515.80. This represents a 0.43 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink.
Vanda Pharmaceuticals Trading Up 2.5 %
Shares of NASDAQ VNDA opened at $4.46 on Wednesday. The firm has a 50-day moving average of $4.59 and a two-hundred day moving average of $4.81. The company has a market capitalization of $260.09 million, a price-to-earnings ratio of -13.94 and a beta of 0.74. Vanda Pharmaceuticals Inc. has a twelve month low of $3.71 and a twelve month high of $6.75.
Vanda Pharmaceuticals (NASDAQ:VNDA - Get Free Report) last issued its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, beating analysts' consensus estimates of ($0.14) by $0.06. Vanda Pharmaceuticals had a negative return on equity of 3.49% and a negative net margin of 9.51%. The business had revenue of $53.19 million for the quarter, compared to the consensus estimate of $51.00 million. As a group, research analysts predict that Vanda Pharmaceuticals Inc. will post -1.12 earnings per share for the current year.
Analyst Upgrades and Downgrades
VNDA has been the subject of a number of research analyst reports. StockNews.com initiated coverage on shares of Vanda Pharmaceuticals in a research note on Wednesday, February 5th. They issued a "hold" rating for the company. HC Wainwright boosted their target price on shares of Vanda Pharmaceuticals from $18.00 to $20.00 and gave the company a "buy" rating in a research note on Tuesday, February 18th.
View Our Latest Report on Vanda Pharmaceuticals
Institutional Investors Weigh In On Vanda Pharmaceuticals
A number of institutional investors have recently made changes to their positions in the stock. BNP Paribas Financial Markets grew its stake in Vanda Pharmaceuticals by 1,184.6% in the third quarter. BNP Paribas Financial Markets now owns 62,238 shares of the biopharmaceutical company's stock valued at $292,000 after acquiring an additional 57,393 shares during the period. FMR LLC raised its stake in Vanda Pharmaceuticals by 25.9% in the 3rd quarter. FMR LLC now owns 149,739 shares of the biopharmaceutical company's stock valued at $702,000 after acquiring an additional 30,802 shares during the period. Massachusetts Financial Services Co. MA bought a new stake in Vanda Pharmaceuticals in the 3rd quarter valued at $864,000. GSA Capital Partners LLP acquired a new position in Vanda Pharmaceuticals in the 3rd quarter valued at $143,000. Finally, Barclays PLC grew its holdings in Vanda Pharmaceuticals by 128.2% in the 3rd quarter. Barclays PLC now owns 154,297 shares of the biopharmaceutical company's stock valued at $722,000 after buying an additional 86,677 shares in the last quarter. 88.14% of the stock is owned by institutional investors and hedge funds.
Vanda Pharmaceuticals Company Profile
(
Get Free Report)
Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
